Lentivirus-modified hematopoietic stem cell gene therapy for advanced symptomatic juvenile metachromatic leukodystrophy: a long-term follow-up pilot study
Protein & Cell · 04.01.2025 · 16 (1) · 16-27
DOI: 10.1093/procel/pwae037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein & Cell, online erschienen am 25.06.2024. Verfasst von Zhao Zhang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Cord Blood Bank, Guangzhou Institute of Eugenics and Perinatology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guang…. Hauptthemen laut MEDLINE: Leukodystrophy, Metachromatic, Genetic Therapy, Hematopoietic Stem Cell Transplantation, Lentivirus. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Poland Fundacja Siepomaga, JS Foundation.
Abstract (Originalsprache)
Metachromatic leukodystrophy (MLD) is an inherited disease caused by a deficiency of the enzyme arylsulfatase A (ARSA). Lentivirus-modified autologous hematopoietic stem cell gene therapy (HSCGT) has recently been approved for clinical use in pre and early symptomatic children with MLD to increase ARSA activity. Unfortunately, this advanced therapy is not available for most patients with MLD who have progressed to more advanced symptomatic stages at diagnosis. Patients with late-onset juvenile MLD typically present with a slower neurological progression of symptoms and represent a significant burden to the economy and healthcare system, whereas those with early onset infantile MLD die within a few years of symptom onset. We conducted a pilot study to determine the safety and benefit of HSCGT in patients with postsymptomatic juvenile MLD and report preliminary results. The safety profile of HSCGT was favorable in this long-term follow-up over 9 years. The most common adverse events (AEs) within 2 months of HSCGT were related to busulfan conditioning, and all AEs resolved. No HSCGT-related AEs and no evidence of distorted hematopoietic differentiation during long-term follow-up for up to 9.6 years. Importantly, to date, patients have maintained remarkably improved ARSA activity with a stable disease state, including increased Functional Independence Measure (FIM) score and decreased magnetic resonance imaging (MRI) lesion score. This long-term follow-up pilot study suggests that HSCGT is safe and provides clinical benefit to patients with postsymptomatic juvenile MLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cord Blood Bank, Guangzhou Institute of Eugenics and Perinatology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
- State Key Laboratory of Pharmaceutical Biotechnology, Department of Medicine, The University of Hong Kong, Hong Kong SAR 999077, China.
- Department of Haematology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
- Department of Pharmacy, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen University School of Medicine, Shenzhen University, Shenzhen 518060, China.
- Shenzhen University of Advanced Technology, Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 51…
- Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518026, China.
ORCID-Profile: Li Huang, Qizhou Lian
Förderung
- Poland Fundacja Siepomaga, JS Foundation
Zitieren
APA
Zhang, Z., Jiang, H., Huang, L., Liu, S., Zhou, X., Cai, Y., Li, M., Gao, F., Liang, X., Tsang, K. S., Chen, G., Ma, C. Y., Chai, Y. H., Liu, H., Yang, C., Yang, M., Zhang, X., Han, S., Du, X., …, & Lian, Q. (2025). Lentivirus-modified hematopoietic stem cell gene therapy for advanced symptomatic juvenile metachromatic leukodystrophy: a long-term follow-up pilot study. Protein & Cell, 16(1), 16-27. https://doi.org/10.1093/procel/pwae037
Vancouver
Zhang Z, Jiang H, Huang L, Liu S, Zhou X, Cai Y, et al. Lentivirus-modified hematopoietic stem cell gene therapy for advanced symptomatic juvenile metachromatic leukodystrophy: a long-term follow-up pilot study. Protein & Cell. 2025;16(1):16-27. doi:10.1093/procel/pwae037
BibTeX
@article{Zhang2025,
author = {Zhang, Zhao and Jiang, Hua and Huang, Li and Liu, Sixi and Zhou, Xiaoya and Cai, Yun and Li, Ming and Gao, Fei and Liang, Xiaoting and Tsang, Kam-Sze and Chen, Guangfu and Ma, Chui-Yan and Chai, Yuet-Hung and Liu, Hongsheng and Yang, Chen and Yang, Mo and Zhang, Xiaoling and Han, Shuo and Du, Xin and Chen, Ling and Hwu, Wuh-Liang and Zhuo, Jiacai and Lian, Qizhou},
title = {Lentivirus-modified hematopoietic stem cell gene therapy for advanced symptomatic juvenile metachromatic leukodystrophy: a long-term follow-up pilot study},
journal = {Protein & Cell},
year = {2025},
volume = {16},
number = {1},
pages = {16--27},
doi = {10.1093/procel/pwae037}
}
EUVIMED